Compare STRIDES PHARMA SCIENCE with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs FRESENIUS KABI ONCO. - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE FRESENIUS KABI ONCO. STRIDES PHARMA SCIENCE/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 14.8 22.1 66.9% View Chart
P/BV x 0.9 3.1 28.1% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 STRIDES PHARMA SCIENCE   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
FRESENIUS KABI ONCO.
Mar-13
STRIDES PHARMA SCIENCE/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs1,147176 651.7%   
Low Rs64279 817.8%   
Sales per share (Unadj.) Rs317.237.7 841.8%  
Earnings per share (Unadj.) Rs7.85.1 154.0%  
Cash flow per share (Unadj.) Rs25.16.7 372.7%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs274.342.5 644.6%  
Shares outstanding (eoy) m89.50158.23 56.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.83.4 83.5%   
Avg P/E ratio x114.025.0 456.4%  
P/CF ratio (eoy) x35.718.9 188.6%  
Price / Book Value ratio x3.33.0 109.0%  
Dividend payout %25.50-   
Avg Mkt Cap Rs m80,05820,135 397.6%   
No. of employees `0002.51.2 217.6%   
Total wages/salary Rs m4,341703 617.2%   
Avg. sales/employee Rs Th11,325.85,176.2 218.8%   
Avg. wages/employee Rs Th1,731.4610.4 283.6%   
Avg. net profit/employee Rs Th280.1699.6 40.0%   
INCOME DATA
Net Sales Rs m28,3945,963 476.2%  
Other income Rs m94118 5,225.6%   
Total revenues Rs m29,3345,981 490.5%   
Gross profit Rs m3,9651,430 277.3%  
Depreciation Rs m1,540258 597.3%   
Interest Rs m1,962-26 -7,547.7%   
Profit before tax Rs m1,4031,216 115.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-436-68 639.9%   
Tax Rs m97342 28.4%   
Profit after tax Rs m702806 87.1%  
Gross profit margin %14.024.0 58.2%  
Effective tax rate %6.928.1 24.6%   
Net profit margin %2.513.5 18.3%  
BALANCE SHEET DATA
Current assets Rs m24,8365,102 486.8%   
Current liabilities Rs m18,9932,385 796.2%   
Net working cap to sales %20.645.6 45.2%  
Current ratio x1.32.1 61.1%  
Inventory Days Days71150 47.3%  
Debtors Days Days113113 100.1%  
Net fixed assets Rs m34,2895,148 666.0%   
Share capital Rs m895158 565.7%   
"Free" reserves Rs m23,6516,556 360.8%   
Net worth Rs m24,5466,732 364.6%   
Long term debt Rs m15,513952 1,629.2%   
Total assets Rs m65,43710,388 629.9%  
Interest coverage x1.7-45.8 -3.7%   
Debt to equity ratio x0.60.1 446.8%  
Sales to assets ratio x0.40.6 75.6%   
Return on assets %4.17.5 54.2%  
Return on equity %2.912.0 23.9%  
Return on capital %6.914.6 47.2%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m15,6975,298 296.3%   
Fx outflow Rs m7351,772 41.5%   
Net fx Rs m14,9623,525 424.4%   
CASH FLOW
From Operations Rs m1,8711,274 146.8%  
From Investments Rs m5,826-1,204 -483.8%  
From Financial Activity Rs m-10,157-196 5,179.4%  
Net Cashflow Rs m-2,615-126 2,070.4%  

Share Holding

Indian Promoters % 27.7 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 37.8 0.3 12,600.0%  
FIIs % 8.6 9.6 89.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 9.1 284.6%  
Shareholders   56,241 42,599 132.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   GLENMARK PHARMA  FULFORD INDIA  PROCTER & GAMBLE HEALTH  DIVIS LABORATORIES  UNICHEM LAB  

Compare STRIDES PHARMA SCIENCE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of STRIDES PHARMA SCIENCE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES PHARMA SCIENCE. Also includes updates on the valuation of STRIDES PHARMA SCIENCE.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Sep 20, 2019 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 5-YR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS